New Indication for the Use of Xtandi® (enzalutamide) Capsules
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile
In the Phase III PREVAIL trial, men receiving enzalutamide therapy exhibited a statistically significant improvement in both overall survival and delayed time to radiographic progression or death as compared to those on placebo1 . Read more